



**Note: Some links to federal government websites may be broken due to presidential executive orders.**

---



[Home](#) / [DOH Digest](#)

/ [See A Summary On The Status Of Measles Outbreaks And COVID Vaccination In Washington And The U.S.](#)

# See a summary on the status of measles outbreaks and COVID vaccination in Washington and the U.S.

June 05, 2025

We have collected health updates about measles and COVID-19 to assist health care providers and public health professionals with navigating the current public health landscape.

There were 1,088 confirmed measles cases reported in 33 jurisdictions across the U.S. in May. So far in 2025, Washington has had 6 measles cases in 2 counties (King and Snohomish). There have been no outbreaks in Washington this year. An outbreak is defined as 3 or more related cases. Visit the [CDC measles data page](#) for ongoing updates.

Earlier this week in a social media posting, Health & Human Services (HHS) Secretary Robert F. Kennedy Jr. announced changes to the recommendations for COVID-19 vaccines for healthy pregnant women and healthy children on the CDC's [immunization schedules](#).

DOH has yet to receive or locate any formal communication or publication about this change from CDC, and at the time of this statement their immunization schedule remains unchanged. Providers should continue to offer and administer COVID-19 vaccines to all patients 6 months and older.

DOH will continue to monitor these events and keep our partners informed of any changes to our own guidance and recommendations. Reach out to the [Childhood Vaccine Program](#) or the [Adult Vaccine Program](#) if you have questions.

Timeline of recent events:

- On May 27, 2025, federal announcement [COVID-19 vaccine will no longer be among the recommended vaccines for pregnant women and healthy children](#).
- On May 22, 2025, [FDA advisers recommended manufacturers make no changes to the COVID-19 vaccine](#) that will be available for boosters later this summer. Read the official announcement: [COVID-19 Vaccines \(2025-2026\) for Use in the US Beginning in Fall 2025](#). The [Vaccines and Related Biological Products Advisory Committee](#), met to discuss and make recommendations on the selection of the 2025-2026 formula for COVID-19 vaccines for use in the U.S. The committee voted 9-0 that the 2025-26 vaccines should stay the same, containing a single JN.1 strain, which has been dominant globally since 2024.
- The FDA has not held any further meetings nor issued a final rule or policy to clarify whether this year's COVID-19 vaccine boosters would be required to conduct new trials. The FDA framework [published May 20, 2025, in the New England Journal of Medicine](#), urges companies to conduct large, lengthy studies before tweaked vaccines can be approved for healthier people.
- On May 17, 2025, the [FDA gave full approval for Novavax's COVID-19 vaccine](#), which previously only had emergency use authorization. The FDA limited the vaccine's use to adults older than 65 and anyone older than 12 at high risk. In June 2025, ACIP is expected to consider its recommendations for use of COVID-19 vaccines for preventing COVID-19 disease.
- On April 17, 2025, the FDA instructed [Pfizer](#) and [Moderna](#) to update labeling to expand a warning about myocarditis and pericarditis. Pfizer's label warned of an elevated risk in men 12- to 17-year-olds, Moderna's in men 18- to 24-year-olds. Both will now cite an elevated risk in men aged 16 years to 25 years.

## Helpful Links

[Give out pocket-sized immunization schedules for kids and teens](#)  
[DOH Immunization Forms and Publications page](#)